Amendments to the Claims:

Claim 1. (original) A compound of the Formula (I)



wherein:

Y is OH, halogen, or CF_3;

Z is H, OH, OR_1, halogen, or CF_3;

X_1 and X_2 are independently C or N; and

A is selected from the group consisting of:














wherein n is 1-8; X_3 is O, S, SO, SO_2, NH, or NR_1; Q is NH or NR_1; and V_{1-4} are each independently OH, OR_2, or halogen; R_1 and R_2 are independently H, alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycle, substituted heterocycle, acyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl or dialkylaminocarbonyl; the dashed lines indicate the presence of optional double bonds; and L is the point of bonding of A to the compound structure, with the proviso that Z is not H when Y is OH, Cl or Br and A is



,


,


or



and pharmaceutically acceptable salts thereof.

Claim 2. (original) A compound according to Claim 1, wherein Y is flourine.

Claim 3. (original) A compound selected from the group consisting of:

1,5-Bis-(2,4-difluorophenyl)penta-1,4-diene-3-one;

3,5-Bis-(2-fluorobenzylidene)-piperidin-4-one-acetate; and

3,5-Bis-(2-hydroxybenzylidene)tetrahydro-4-H-pyran-4-one.

Claim 4. (original) A pharmaceutical formulation comprising a compound of Claim 1 in a pharmaceutically acceptable carrier.

Claim 5. (original) A method of treating cancerous tissue in a subject, comprising administering to the subject an effective amount of a compound of formula (I)



wherein:

Y is OH, halogen, or CF_3;

Z is H, OH, OR_1, halogen, or CF_3;

X_1 and X_2 are independently C or N; and

A is selected from the group consisting of:



,


,


,


,


,


,


,


,


,


,


,


, and


wherein n is 1-8; X_3 is O, S, SO, SO_2, NH, or NR_1; Q is NH or NR_1; and V_{1-4} are each independently OH, OR_2, or halogen; R_1 and R_2 are independently H, alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycle, substituted heterocycle, acyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl or

dialkylaminocarbonyl; the dashed lines indicate the presence of optional double bonds; and L is the point of bonding of A to the compound structure, with the proviso that Z is not H when Y is OH, Cl or Br and A is



,


,


or



and pharmaceutically acceptable salts thereof.

Claim 6. (original) A method according to Claim 5, wherein the effective amount comprises an amount sufficient to inhibit VEGF production in the cancerous tissue.

Claim 7. (original) A method according to Claim 5, wherein the effective amount comprises an amount sufficient to inhibit TF production in the cancerous tissue.

Claim 8. (original) A method according to Claim 5, wherein said administering step comprises administering an effective amount of the compound in a pharmaceutically acceptable carrier.

Claims 9-12 (cancelled).